LO
LIPAC Oncology
The startup develops localized pro-liposomal formulations of paclitaxel to target tumors in difficult-to-reach areas of the body, enhancing drug persistence and deep tissue penetration. This approach improves treatment efficacy for cancer patients while minimizing systemic exposure and associated toxicity.
- Biotechnology
Updated 6 months ago
Funding
Raised to date
$370KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops localized pro-liposomal formulations of paclitaxel to target tumors in difficult-to-reach areas of the body, enhancing drug persistence and deep tissue penetration. This approach improves treatment efficacy for cancer patients while minimizing systemic exposure and associated toxicity.